期刊
PHARMACEUTICALS
卷 14, 期 6, 页码 -出版社
MDPI
DOI: 10.3390/ph14060546
关键词
coronavirus disease; SARS-CoV-2; flavonoids; glycosyl flavonoids; antivirals; spike glycoprotein; protease 3CL(pro)
资金
- University of Aveiro
- Fundacao para a Ciencia e Tecnologia, FCT/MEC through the LAQV-REQUIMTE [UIDB/50006/2020]
- Principado de Asturias [FICYT IDI/2018/000181]
- MINECO [PID2019-109253RB-I00]
The global spread of the COVID-19 pandemic has highlighted the need for effective antiviral treatments, with researchers exploring glycosylated flavonoids as potential natural sources for managing COVID-19.
The COVID-19 pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has spread all over the world, creating a devastating socio-economic impact. Even though protective vaccines are starting to be administered, an effective antiviral agent for the prevention and treatment of COVID-19 is not available yet. Moreover, since new and deadly CoVs can emerge at any time with the potential of becoming pandemics, the development of therapeutic agents against potentially deadly CoVs is a research area of much current interest. In the search for anti-coronaviral drugs, researchers soon turned their heads towards glycosylated flavonoids. Glycosyl flavonoids, widespread in the plant kingdom, have received a lot of attention due to their widely recognized antioxidant, anti-inflammatory, neuroprotective, anticarcinogenic, antidiabetic, antimicrobial, and antiviral properties together with their capacity to modulate key cellular functions. The wide range of biological activities displayed by glycosyl flavonoids, along with their low toxicity, make them ideal candidates for drug development. In this review, we examine and discuss the up-to-date developments on glycosyl flavonoids as evidence-based natural sources of antivirals against coronaviruses and their potential role in the management of COVID-19.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据